KORU Medical Q3 net loss $1.1M; revenue $6.0M, 9% sequential growth

KORU Medical Systems, Inc.

2021-Q3 EPS reported -$0.08 revenue$16,999,669

Net revenue $6.0M, 9% sequential growth; adjusted net revenue up 9% YoY excluding prior year inventory stocking.
Net loss $1.1M ($0.02 per share) vs net income $0.2M ($0.01) in Q3 2020.
Gross margin 57.9%, down from 64.8% due to manufacturing transition delays and scrap reserve.
Received FDA 510(k) clearance for Hizentra 20ml prefilled syringe with Freedom Edge system.
Three leadership hires and strategic plan update scheduled for December 2, 2021.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.